Oura Plans September IPO with Valuation Exceeding $16 Billion

Washington DC, United States Aug 25, 2026 ALN: Oura, the smart ring maker, with offices in San Francisco and Finland, is reportedly planning to raise up to $3 billion as soon as next month in a U.S. IPO that values the more than 900-person company at north of $16 billion, according to Bloomberg. The outlet adds that investors are expected to sell a major chunk of stock in the offering.

A $16 billion valuation would mark an enormous jump from the $10.9 billion valuation Oura was assigned last September, when it closed an $875 million Series E round backed by Fidelity, ICONIQ, Whale Rock, and Atreides, joining earlier backers like Dexcom, The Chernin Group, Forerunner Ventures, Coatue, and Temasek. This significant increase in valuation reflects the growing interest in wearable technology and the health and wellness sector, which has seen a surge in demand as consumers become more health-conscious and tech-savvy.

The wearables space has gotten crowded fast. In recent years, numerous companies have launched products aimed at monitoring various aspects of health and fitness, making it a competitive market. Samsung launched its own ring, the Galaxy Ring, two years ago, signaling its entry into this growing segment. However, Oura’s most direct rival may be the fitness band maker Whoop, which has undergone its own reinvention. Once a performance tool primarily targeted at elite athletes and young men, Whoop has spent the past year courting a much broader audience, layering in hormone tracking and blood-panel testing for perimenopause and thyroid health. This strategic pivot has driven its own valuation up to $10 billion back in March, illustrating the potential for growth in the wearables market.

Oura has followed a similar path, evolving from its initial niche of biohacking CEOs into a more mainstream sleep-and-recovery brand. This evolution has been crucial in attracting a wider customer base, as more individuals seek to understand and improve their sleep patterns and overall health. The company's smart ring, which tracks various metrics such as sleep quality, heart rate, and activity levels, has gained popularity among consumers looking for innovative ways to monitor their health.

Oura announced in May that it had filed confidentially for an IPO, a common practice for companies looking to go public while keeping sensitive financial information private until closer to the offering date. This filing marks a significant step for the company as it prepares to enter the public market, which could provide it with the capital needed for further expansion and product development.

The company has projected impressive revenue growth, claiming it generated $500 million in revenue in 2024, roughly $1 billion in 2025, and close to $2 billion in revenue in 2026. These projections, while ambitious, will be scrutinized once its S-1 filing becomes publicly available. Investors will be particularly interested in the company's financial health, growth strategies, and market positioning as it prepares for its IPO.

However, not all of Oura’s recent attention has been positive. A proposed class action lawsuit filed last week in San Francisco accuses Oura of misleading consumers about the accuracy of its sleep tracking features. Among other complaints in the filing, Oura is accused of not just claiming “to measure a heartbeat or a temperature, but the exact stage of sleep the wearer is in—which in reality requires electrodes in the scalp and sensors on the eyes, as only a hospital or other clinical setting can do.” This allegation raises important questions about the ethical responsibilities of wearable technology companies in accurately representing their products and the data they provide to consumers.

In a statement sent over the weekend, a spokesperson pushed back against claims in that suit, stating that the company plans to “defend against them in the appropriate legal forum” and that “[w]hile Oura Ring is not a medical device or a substitute for a clinical sleep study, Oura’s sleep staging has been validated and compared favorably in multiple studies against polysomnography, the gold standard.” This defense highlights the company's commitment to transparency and accuracy in its claims, which is crucial in maintaining consumer trust, especially in a market that increasingly values data privacy and accuracy.

The statement continued on to say that “[m]ultiple third-party, independent studies support our claims of accuracy and we have transparently reported on the mechanisms and measures that inform Oura’s sleep staging.” This emphasis on independent validation is particularly important in the wearables market, where consumers are often skeptical of the claims made by companies regarding the effectiveness and accuracy of their products.

As Oura moves closer to its IPO, the outcome of the lawsuit and its implications for the company's reputation and market position will be closely monitored by investors and industry analysts alike. The wearables market is expected to continue growing, driven by consumer demand for health monitoring technology, but companies will need to navigate the challenges of competition and regulatory scrutiny as they seek to establish themselves as leaders in this evolving landscape.